3/7/2023 0 Comments Kim panzarella dermatologist![]() Further evidence is needed to develop a prognostic model and stratify individuals at high risk of developing SCC, to improve the evidence base for this common cancer and to optimise clinical management. Comparison of outcomes after different treatments should be interpreted cautiously owing to biases inherent in the types of study included, and lack of direct comparisons to enable the estimation of relative treatment effect. Evidence was limited for laser treatment (1 study) and for topical and systemic treatments (mostly single case reports or small non-comparative series with limited follow-up).Ĭonclusions Many observational studies have looked at different treatment modalities for SCC, but the evidence base for the effectiveness of these interventions is poor. After an apparently successful initial response of SCCs to photodynamic therapy, pooled average recurrence of 26.4% (12.3% to 43.7% 8 studies) was significantly higher than other treatments. After Mohs micrographic surgery, the pooled estimate of local recurrence during variable follow-up periods from 10 studies was 3.0% (2.2% to 3.9%), which was non-significantly lower than the pooled average local recurrence of 5.4% (2.5% to 9.1%) after standard surgical excision (12 studies), and 6.4% (3.0% to 11.0%) after external radiotherapy (7 studies). Pooled estimates of recurrence of SCCs were lowest after cryotherapy (0.8% (95% confidence interval 0.1% to 2%)) and curettage and electrodesiccation (1.7% (0.5% to 3.4%)), but most treated SCCs were small, low risk lesions. ![]() Results 118 publications were included, covering seven treatment modalities. Meta-analysis was performed where appropriate using a random effects model to estimate the pooled proportion of an event with 95% confidence intervals. Data were extracted independently by two reviewers. Studies were excluded if data for primary cutaneous SCC was not separable from other data. Review methods Observational studies of interventions for primary, non-metastatic, invasive, SCC of the skin that reported recurrence during follow-up, quality of life, initial response to treatment, adverse events, cosmetic appearance, or death from disease. In no event shall the AAD be liable for any decision made or action taken in reliance on the information contained therein.Ĭopyright © 2019 American Academy of Dermatology Association.Objectives To assess the effects of treatments for non-metastatic invasive squamous cell carcinoma (SCC) of the skin using evidence from observational studies, given the paucity of evidence from randomised controlled trials.ĭesign Systematic review of observational studies.ĭata sources Medline, Embase, to December 2012. Neither the database, nor any part of the data, listings, profiles, or other constituent elements may be downloaded, republished, or duplicated, in whole or in part, for commercial purposes, purposes of compiling a mailing list or any other list ofĭermatologists, or for any other purposes without the prior express written permission of the AAD.Īlthough the AAD undertakes reasonable efforts to keep the information in "Find a Dermatologist" up to date, the AAD does not warrant the accuracy, completeness, timeliness, or in any way endorse the individuals described therein. It is intended to provide the public with quick access to information on dermatologists who are members of "Find a Dermatologist" is produced by the American Academy of Dermatology (AAD) as references of professional information on individual dermatologists. ![]() Special Proprietary Notice and Disclaimer
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |